X4 Pharmaceuticals, Inc. (XFOR) stock analysis

In our weekly check, X4 Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 11.

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as XFOR.

What our checks show for XFOR

Red flags

• Operating profit does not cover the interest bill (-10.1x): interest is paid from cash or new debt.
• The net margin fell by 569 points over 5 years, to -569%: the company keeps less of each sale as profit.
• Weak EPS forecast
• Earnings per share fell 70.3% a year over the last 3 years.
• The company is losing money: the net margin is -569%.
• Free cash flow is negative (-559% of revenue): the business spends more cash than it brings in.
• The price swings a lot: 74.5% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 100% from a peak. Would you have held through that?
• The share count grew by 614% in 2 years: each shareholder owns a smaller slice.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
• Pay in shares equals 0% of free cash flow: it dilutes shareholders.

Warning signs

• Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
• A small company (market value $321 million): usually riskier and followed by fewer analysts.
• The stock is still below its previous peak.

Strengths

• Debt is low: 0.5x equity.
• The gross margin is 81.2% and has risen by 81.2 points: pricing power is holding.
• Analysts expect revenue to grow about 39.3% a year over the next years.
• Analysts expect the net margin to improve by 469 points from today's -569%.
• Beta 0.35: the stock usually moves less than the market.

Next earnings report: 2026-11-04

Similar companies

SGMT · KYTX · OBIO · MPLT · BNTC · CAPR

Questions

What grade does X4 Pharmaceuticals, Inc. (XFOR) have?

In our weekly check, X4 Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 11. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of XFOR stock?

This week's biggest flags for X4 Pharmaceuticals, Inc.: Weak interest cover, Margins falling, Weak EPS forecast. In total 14 of 21 checks show a warning or a red flag.

What does X4 Pharmaceuticals, Inc. do?

X4 Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as XFOR.

When does X4 Pharmaceuticals, Inc. report earnings next?

The next earnings report is expected on 2026-11-04. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis